Non‑Small Cell Lung Cancer | Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer

Featuring perspectives from Drs Alexander Spira and Helena Yu, including the following topics:

• Introduction
  • What is an antibody-drug conjugate? (0:00)
• "HER2-Positive" Non-Small Cell Lung Cancer (NSCLC)
  • Case: A woman in her mid 50s with HER2 insertion in exon 20 — Dr Yu (8:42)
• Targeting HER3 in NSCLC
  • Case: A man in his early 60s with lung cancer with an EGFR mutation — Dr Yu (25:23)
• TROP2-Directed Treatment
  • Case: A woman in her early 50s with lung cancer with a KRAS G12V mutation — Dr Spira (36:57)
  • Case: A woman in her mid 60s with metastatic NSCLC and an EGFR exon 19 deletion — Dr Spira (39:32)
• Novel Agents
  • Mechanism of action of tusamitamab ravtansine and telisotuzumab vedotin (54:15)

CME information and select publications